{"doc_id": "32527346", "type of study": "Therapy", "title": "", "abstract": "[Effect of Xuebijing injection on inflammatory markers and disease outcome of coronavirus disease 2019].\nTo observe the influence of Xuebijing injection on the inflammatory markers and prognosis of coronavirus disease 2019 (COVID-19) patients.\nSixty severe COVID-19 patients admitted to Changsha Public Health Treatment Center (North Hospital of the First Hospital of Changsha City) from January to March in 2020 were randomly divided into routine treatment group, Xuebijing 50 mL group and Xuebijing 100 mL group, with 20 cases in each group.\nThe routine treatment group was treated according to the National Health Commission's guide for COVID-19.\nOn the basis of conventional treatment, Xuebijing injection was injected by 50 mL twice a day for 7 days in Xuebijing 50 mL group, while by 100 mL twice a day for 7 days in Xuebijing 100 mL group.\nThe blood routine test, C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), acute physiology and chronic health evaluation II (APACHE II) score, 2019 novel coronavirus (2019-nCoV) nucleic acid test and disease classification of three groups before and 8 days after treatment were observed.\n(1) After treatment, the white blood cell count (WBC) and lymphocyte count (LYM) of three groups increased, meanwhile CRP and ESR decreased.\nCompared with routine treatment group, the WBC count of Xuebijing 100 mL group after treatment significantly increased (\u00d7109/L: 7.12\u00b10.55 vs. 5.67\u00b10.51, P < 0.05), and the levels of CRP and ESR in Xuebijing 50 mL and 100 mL groups significantly decreased [CRP (mg/L): 32.3\u00b14.6, 28.0\u00b16.2 vs. 37.3\u00b15.9; ESR (mm/1 h): 45.9\u00b15.7, 40.5\u00b17.4 vs. 55.3\u00b16.6, all P < 0.05].\nCompared with Xuebijing 50 mL group, the increase of WBC, and the decrease of CRP and ESR were more significant in Xuebijing 100 mL group [WBC (\u00d7109/L): 7.12\u00b10.55 vs. 5.82\u00b10.49, CRP (mg/L): 28.0\u00b16.2 vs. 32.3\u00b14.6, ESR (mm/1 h): 40.5\u00b17.4 vs. 45.9\u00b15.7, all P < 0.05].\n(2) After treatment, the APACHE II score of three groups decreased.\nIn Xuebijing 100 mL group, the APACHE II score after treatment was significantly lower than those in routine treatment and Xuebijing 50 mL groups (12.3\u00b11.5 vs. 16.5\u00b11.6, 15.9\u00b11.4, both P < 0.05).\nAfter treatment, the 2019-nCoV nucleic acid test in three groups partly turned negative, with 9 cases in routine treatment group, 8 cases in Xuebijing 50 mL group and 9 cases in Xuebijing 100 mL group, without significant difference (P > 0.05).\nThe conditions of patients in the three groups were improved after treatment, among them, 8 cases in the routine treatment group were transformed into common type, 1 case into critical type; 9 cases and 12 cases of Xuebijing 50 mL group and 100 mL group were transformed into common type respectively.\nXuebijing 100 mL group was improved more obviously than Xuebijing 50 mL group and routine treatment group (both P < 0.05).\nThe Xuebijing injection can effectively improve the inflammatory markers and prognosis of severe COVID-19 patients.\n", "Evidence Map": {"Enrollment": [{"term": "coronavirus disease", "negation": "affirmed", "UMLS": {}, "start": 79, "end": 98}, {"term": "coronavirus disease 2019 ( COVID-19", "negation": "affirmed", "UMLS": {}, "start": 93, "end": 128}, {"term": "severe COVID-19", "negation": "affirmed", "UMLS": {}, "start": 6, "end": 21}, {"term": "severe COVID-19", "negation": "affirmed", "UMLS": {}, "start": 90, "end": 105}], "Comparison Results": [], "Study Arm 1 Results": [], "Study Arm 2 Results": [], "Hypothesis": []}, "Sentence-level breakdown": [{"Section": "TITLE", "Text": "[ Effect of Xuebijing injection on inflammatory markers and disease outcome of coronavirus disease 2019 ] .", "Evidence Elements": {"Participant": [{"term": "coronavirus disease", "negation": "affirmed", "UMLS": {}, "start": 79, "end": 98}], "Intervention": [{"term": "Xuebijing injection", "negation": "affirmed", "UMLS": {}, "start": 12, "end": 31}], "Outcome": [{"term": "inflammatory markers", "negation": "affirmed", "UMLS": {}, "start": 35, "end": 55}, {"term": "disease outcome", "negation": "affirmed", "UMLS": {}, "start": 60, "end": 75}], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "OBJECTIVE", "Text": "To observe the influence of Xuebijing injection on the inflammatory markers and prognosis of coronavirus disease 2019 ( COVID-19 ) patients .", "Evidence Elements": {"Participant": [{"term": "coronavirus disease 2019 ( COVID-19", "negation": "affirmed", "UMLS": {}, "start": 93, "end": 128}], "Intervention": [{"term": "Xuebijing injection", "negation": "affirmed", "UMLS": {}, "start": 28, "end": 47}], "Outcome": [{"term": "inflammatory markers", "negation": "affirmed", "UMLS": {}, "start": 55, "end": 75}, {"term": "prognosis", "negation": "affirmed", "UMLS": {}, "start": 80, "end": 89}], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "METHODS", "Text": "Sixty severe COVID-19 patients admitted to Changsha Public Health Treatment Center ( North Hospital of the First Hospital of Changsha City ) from January to March in 2020 were randomly divided into routine treatment group , Xuebijing 50 mL group and Xuebijing 100 mL group , with 20 cases in each group .", "Evidence Elements": {"Participant": [{"term": "severe COVID-19", "negation": "affirmed", "UMLS": {}, "start": 6, "end": 21}], "Intervention": [{"term": "routine treatment", "negation": "affirmed", "UMLS": {}, "start": 198, "end": 215}, {"term": "Xuebijing", "negation": "affirmed", "UMLS": {}, "start": 224, "end": 233}, {"term": "Xuebijing", "negation": "affirmed", "UMLS": {}, "start": 224, "end": 233}], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "METHODS", "Text": "The routine treatment group was treated according to the National Health Commission 's guide for COVID-19 .", "Evidence Elements": {"Participant": [], "Intervention": [{"term": "routine treatment", "negation": "affirmed", "UMLS": {}, "start": 4, "end": 21}], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "METHODS", "Text": "On the basis of conventional treatment , Xuebijing injection was injected by 50 mL twice a day for 7 days in Xuebijing 50 mL group , while by 100 mL twice a day for 7 days in Xuebijing 100 mL group .", "Evidence Elements": {"Participant": [], "Intervention": [{"term": "conventional treatment", "negation": "affirmed", "UMLS": {}, "start": 16, "end": 38}, {"term": "Xuebijing injection", "negation": "affirmed", "UMLS": {}, "start": 41, "end": 60}, {"term": "Xuebijing 50 mL", "negation": "affirmed", "UMLS": {}, "start": 109, "end": 124}, {"term": "Xuebijing 100", "negation": "affirmed", "UMLS": {}, "start": 175, "end": 188}], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "METHODS", "Text": "The blood routine test , C-reactive protein ( CRP ) , erythrocyte sedimentation rate ( ESR ) , acute physiology and chronic health evaluation II ( APACHE II ) score , 2019 novel coronavirus ( 2019-nCoV ) nucleic acid test and disease classification of three groups before and 8 days after treatment were observed .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [{"term": "blood routine test", "negation": "affirmed", "UMLS": {}, "start": 4, "end": 22}, {"term": "C-reactive protein ( CRP )", "negation": "affirmed", "UMLS": {}, "start": 25, "end": 51}, {"term": "erythrocyte sedimentation rate ( ESR )", "negation": "affirmed", "UMLS": {}, "start": 54, "end": 92}, {"term": "acute physiology and chronic health evaluation II ( APACHE II ) score", "negation": "affirmed", "UMLS": {}, "start": 95, "end": 164}, {"term": "2019 novel coronavirus ( 2019-nCoV ) nucleic acid test", "negation": "affirmed", "UMLS": {}, "start": 167, "end": 221}, {"term": "disease", "negation": "affirmed", "UMLS": {}, "start": 226, "end": 233}], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "RESULTS", "Text": "( 1 ) After treatment , the white blood cell count ( WBC ) and lymphocyte count ( LYM ) of three groups increased , meanwhile CRP and ESR decreased .", "Evidence Elements": {"Participant": [], "Intervention": [{"term": "three", "negation": "affirmed", "UMLS": {}, "start": 91, "end": 96}], "Outcome": [{"term": "white blood cell count ( WBC )", "negation": "affirmed", "UMLS": {}, "start": 28, "end": 58}, {"term": "lymphocyte count ( LYM )", "negation": "affirmed", "UMLS": {}, "start": 63, "end": 87}], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "RESULTS", "Text": "Compared with routine treatment group , the WBC count of Xuebijing 100 mL group after treatment significantly increased ( \u00d7109 / L : 7.12 ##\u00b10.55 vs . 5.67 ##\u00b10.51 , P < 0.05 ) , and the levels of CRP and ESR in Xuebijing 50 mL and 100 mL groups significantly decreased [ CRP ( mg / L ) : 32.3 ##\u00b14.6 , 28.0 ##\u00b16.2 vs . 37.3 ##\u00b15.9 ; ESR ( mm / 1 h ) : 45.9 ##\u00b15.7 , 40.5 ##\u00b17.4 vs . 55.3\u00b16.6 , all P < 0.05 ] .", "Evidence Elements": {"Participant": [], "Intervention": [{"term": "routine treatment", "negation": "affirmed", "UMLS": {}, "start": 14, "end": 31}, {"term": "Xuebijing 100 mL", "negation": "affirmed", "UMLS": {}, "start": 57, "end": 73}, {"term": "Xuebijing 50 mL", "negation": "affirmed", "UMLS": {}, "start": 212, "end": 227}, {"term": "100 mL", "negation": "affirmed", "UMLS": {}, "start": 67, "end": 73}], "Outcome": [{"term": "WBC count", "negation": "affirmed", "UMLS": {}, "start": 44, "end": 53}, {"term": "levels of CRP and ESR", "negation": "affirmed", "UMLS": {}, "start": 187, "end": 208}, {"term": "CRP (", "negation": "affirmed", "UMLS": {}, "start": 272, "end": 277}], "Observation": [{"term": "significantly increased", "negation": "affirmed", "UMLS": {}, "start": 96, "end": 119}, {"term": "L", "negation": "affirmed", "UMLS": {}, "start": 72, "end": 73}, {"term": "7.12 ##\u00b10.55", "negation": "affirmed", "UMLS": {}, "start": 133, "end": 145}, {"term": "5.67 ##\u00b10.51", "negation": "affirmed", "UMLS": {}, "start": 151, "end": 163}, {"term": "significantly decreased", "negation": "affirmed", "UMLS": {}, "start": 246, "end": 269}, {"term": "L )", "negation": "affirmed", "UMLS": {}, "start": 283, "end": 286}, {"term": "32.3 ##\u00b14.6", "negation": "affirmed", "UMLS": {}, "start": 289, "end": 300}, {"term": "28.0", "negation": "affirmed", "UMLS": {}, "start": 303, "end": 307}], "Count": []}, "Evidence Propositions": [{"Intervention": "Xuebijing 100 mL", "Observation": "significantly increased", "Outcome": "WBC count", "Count": ""}, {"Intervention": "routine treatment", "Observation": "7.12 ##\u00b10.55", "Outcome": "WBC count", "Count": ""}, {"Intervention": "Xuebijing 100 mL", "Observation": "7.12 ##\u00b10.55", "Outcome": "WBC count", "Count": ""}, {"Intervention": "100 mL", "Observation": "significantly decreased", "Outcome": "levels of CRP and ESR", "Count": ""}]}, {"Section": "RESULTS", "Text": "Compared with Xuebijing 50 mL group , the increase of WBC , and the decrease of CRP and ESR were more significant in Xuebijing 100 mL group [ WBC ( \u00d7 ##109 / L ) : 7.12 ##\u00b10.55 vs . 5.82 ##\u00b10.49 , CRP ( mg / L ) : 28.0 ##\u00b16.2 vs . 32.3 ##\u00b14.6 , ESR ( mm / 1 h ) : 40.5 ##\u00b17.4 vs . 45.9 ##\u00b15.7 , all P < 0.05 ] .", "Evidence Elements": {"Participant": [], "Intervention": [{"term": "Xuebijing 50 mL", "negation": "affirmed", "UMLS": {}, "start": 14, "end": 29}, {"term": "Xuebijing 100 mL", "negation": "affirmed", "UMLS": {}, "start": 117, "end": 133}], "Outcome": [{"term": "increase of WBC", "negation": "affirmed", "UMLS": {}, "start": 42, "end": 57}, {"term": "decrease of CRP and ESR", "negation": "affirmed", "UMLS": {}, "start": 68, "end": 91}, {"term": "WBC", "negation": "affirmed", "UMLS": {}, "start": 54, "end": 57}, {"term": "CRP (", "negation": "affirmed", "UMLS": {}, "start": 197, "end": 202}], "Observation": [{"term": "more significant", "negation": "affirmed", "UMLS": {}, "start": 97, "end": 113}, {"term": "L )", "negation": "affirmed", "UMLS": {}, "start": 158, "end": 161}, {"term": "7.12 ##\u00b10.55", "negation": "affirmed", "UMLS": {}, "start": 164, "end": 176}, {"term": "5.82 ##\u00b10.49", "negation": "affirmed", "UMLS": {}, "start": 182, "end": 194}, {"term": "L )", "negation": "affirmed", "UMLS": {}, "start": 158, "end": 161}, {"term": "28.0", "negation": "affirmed", "UMLS": {}, "start": 214, "end": 218}], "Count": []}, "Evidence Propositions": [{"Intervention": ["Xuebijing 50 mL", "Xuebijing 100 mL"], "Observation": "more significant", "Outcome": "decrease of CRP and ESR", "Count": ""}, {"Intervention": "Xuebijing 50 mL", "Observation": "7.12 ##\u00b10.55", "Outcome": "increase of WBC", "Count": ""}, {"Intervention": "Xuebijing 50 mL", "Observation": "7.12 ##\u00b10.55", "Outcome": "WBC", "Count": ""}, {"Intervention": "Xuebijing 100 mL", "Observation": "7.12 ##\u00b10.55", "Outcome": "increase of WBC", "Count": ""}, {"Intervention": "Xuebijing 100 mL", "Observation": "7.12 ##\u00b10.55", "Outcome": "WBC", "Count": ""}, {"Intervention": "Xuebijing 50 mL", "Observation": "28.0", "Outcome": "increase of WBC", "Count": ""}, {"Intervention": "Xuebijing 50 mL", "Observation": "28.0", "Outcome": "CRP (", "Count": ""}, {"Intervention": "Xuebijing 100 mL", "Observation": "28.0", "Outcome": "increase of WBC", "Count": ""}, {"Intervention": "Xuebijing 100 mL", "Observation": "28.0", "Outcome": "CRP (", "Count": ""}]}, {"Section": "RESULTS", "Text": "( 2 ) After treatment , the APACHE II score of three groups decreased .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [{"term": "APACHE II score", "negation": "affirmed", "UMLS": {}, "start": 28, "end": 43}], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "RESULTS", "Text": "In Xuebijing 100 mL group , the APACHE II score after treatment was significantly lower than those in routine treatment and Xuebijing 50 mL groups ( 12.3 ##\u00b11.5 vs . 16.5 ##\u00b11.6 , 15.9 ##\u00b11.4 , both P < 0.05 ) .", "Evidence Elements": {"Participant": [], "Intervention": [{"term": "Xuebijing 100 mL", "negation": "affirmed", "UMLS": {}, "start": 3, "end": 19}, {"term": "routine treatment", "negation": "affirmed", "UMLS": {}, "start": 102, "end": 119}, {"term": "Xuebijing 50 mL", "negation": "affirmed", "UMLS": {}, "start": 124, "end": 139}], "Outcome": [{"term": "APACHE II score after treatment", "negation": "affirmed", "UMLS": {}, "start": 32, "end": 63}], "Observation": [{"term": "significantly lower", "negation": "affirmed", "UMLS": {}, "start": 68, "end": 87}, {"term": "12.3 ##\u00b11.5", "negation": "affirmed", "UMLS": {}, "start": 149, "end": 160}, {"term": "16.5 ##\u00b11.6", "negation": "affirmed", "UMLS": {}, "start": 166, "end": 177}], "Count": []}, "Evidence Propositions": [{"Intervention": ["Xuebijing 100 mL", "routine treatment", "Xuebijing 50 mL"], "Observation": "significantly lower", "Outcome": "APACHE II score after treatment", "Count": ""}, {"Intervention": "Xuebijing 100 mL", "Observation": "12.3 ##\u00b11.5", "Outcome": "APACHE II score after treatment", "Count": ""}, {"Intervention": "Xuebijing 50 mL", "Observation": "16.5 ##\u00b11.6", "Outcome": "APACHE II score after treatment", "Count": ""}]}, {"Section": "RESULTS", "Text": "After treatment , the 2019-nCoV nucleic acid test in three groups partly turned negative , with 9 cases in routine treatment group , 8 cases in Xuebijing 50 mL group and 9 cases in Xuebijing 100 mL group , without significant difference ( P > 0.05 ) .", "Evidence Elements": {"Participant": [], "Intervention": [{"term": "three groups", "negation": "affirmed", "UMLS": {}, "start": 53, "end": 65}, {"term": "routine treatment", "negation": "affirmed", "UMLS": {}, "start": 107, "end": 124}, {"term": "Xuebijing 50 mL", "negation": "affirmed", "UMLS": {}, "start": 144, "end": 159}, {"term": "Xuebijing 100 mL", "negation": "affirmed", "UMLS": {}, "start": 181, "end": 197}], "Outcome": [{"term": "2019-nCoV nucleic acid test", "negation": "affirmed", "UMLS": {}, "start": 22, "end": 49}], "Observation": [{"term": "negative", "negation": "affirmed", "UMLS": {}, "start": 80, "end": 88}, {"term": "significant", "negation": "negated", "UMLS": {}, "start": 214, "end": 225}], "Count": [{"term": "9 cases", "negation": "affirmed", "UMLS": {}, "start": 96, "end": 103}, {"term": "8 cases", "negation": "affirmed", "UMLS": {}, "start": 133, "end": 140}, {"term": "9 cases", "negation": "affirmed", "UMLS": {}, "start": 96, "end": 103}]}, "Evidence Propositions": [{"Intervention": "three groups", "Observation": "negative", "Outcome": "2019-nCoV nucleic acid test", "Count": ""}]}, {"Section": "RESULTS", "Text": "The conditions of patients in the three groups were improved after treatment , among them , 8 cases in the routine treatment group were transformed into common type , 1 case into critical type ; 9 cases and 12 cases of Xuebijing 50 mL group and 100 mL group were transformed into common type respectively .", "Evidence Elements": {"Participant": [], "Intervention": [{"term": "three groups", "negation": "affirmed", "UMLS": {}, "start": 34, "end": 46}, {"term": "routine treatment", "negation": "affirmed", "UMLS": {}, "start": 107, "end": 124}, {"term": "common type", "negation": "affirmed", "UMLS": {}, "start": 153, "end": 164}, {"term": "critical type", "negation": "affirmed", "UMLS": {}, "start": 179, "end": 192}, {"term": "Xuebijing 50 mL", "negation": "affirmed", "UMLS": {}, "start": 219, "end": 234}, {"term": "100 mL", "negation": "affirmed", "UMLS": {}, "start": 245, "end": 251}], "Outcome": [{"term": "conditions", "negation": "affirmed", "UMLS": {}, "start": 4, "end": 14}], "Observation": [{"term": "improved", "negation": "affirmed", "UMLS": {}, "start": 52, "end": 60}], "Count": [{"term": "8 cases", "negation": "affirmed", "UMLS": {}, "start": 92, "end": 99}, {"term": "1", "negation": "affirmed", "UMLS": {}, "start": 167, "end": 168}, {"term": "9 cases", "negation": "affirmed", "UMLS": {}, "start": 195, "end": 202}, {"term": "12 cases", "negation": "affirmed", "UMLS": {}, "start": 207, "end": 215}]}, "Evidence Propositions": [{"Intervention": "three groups", "Observation": "improved", "Outcome": "conditions", "Count": ""}]}, {"Section": "RESULTS", "Text": "Xuebijing 100 mL group was improved more obviously than Xuebijing 50 mL group and routine treatment group ( both P < 0.05 ) .", "Evidence Elements": {"Participant": [], "Intervention": [{"term": "Xuebijing 100 mL", "negation": "affirmed", "UMLS": {}, "start": 0, "end": 16}, {"term": "Xuebijing 50 mL", "negation": "affirmed", "UMLS": {}, "start": 56, "end": 71}, {"term": "routine treatment", "negation": "affirmed", "UMLS": {}, "start": 82, "end": 99}], "Outcome": [], "Observation": [{"term": "improved more obviously", "negation": "affirmed", "UMLS": {}, "start": 27, "end": 50}], "Count": []}, "Evidence Propositions": [{"Intervention": ["Xuebijing 100 mL", "Xuebijing 50 mL", "routine treatment"], "Observation": "improved more obviously", "Outcome": "", "Count": ""}]}, {"Section": "CONCLUSIONS", "Text": "The Xuebijing injection can effectively improve the inflammatory markers and prognosis of severe COVID-19 patients .", "Evidence Elements": {"Participant": [{"term": "severe COVID-19", "negation": "affirmed", "UMLS": {}, "start": 90, "end": 105}], "Intervention": [{"term": "Xuebijing injection", "negation": "affirmed", "UMLS": {}, "start": 4, "end": 23}], "Outcome": [{"term": "inflammatory markers", "negation": "affirmed", "UMLS": {}, "start": 52, "end": 72}, {"term": "prognosis", "negation": "affirmed", "UMLS": {}, "start": 77, "end": 86}], "Observation": [{"term": "improve", "negation": "affirmed", "UMLS": {}, "start": 40, "end": 47}], "Count": []}, "Evidence Propositions": [{"Intervention": "Xuebijing injection", "Observation": "improve", "Outcome": "inflammatory markers", "Count": ""}, {"Intervention": "Xuebijing injection", "Observation": "improve", "Outcome": "prognosis", "Count": ""}]}]}